BioXCel Therapeutics Stock
What was the cause?
BTAI Stock : The shares of BioXCel Therapeutics ( BTAI -0.95 percent) rose by as up to 19.1 percent during the week. As on Thursday afternoon, they the stock was still up 17% over the course of the week, based on data obtained from S&P Global Intelligence. BioXCel Therapeutics’ stock ended last Friday at $17.02 per share and opened on Tuesday at $17.15. The stock hit a record high of $20.27 on Thursday’s early afternoon. The price is the second week of highs in consecutive weeks for shares of the company.
What’s the question?
Two analysts recently updated their opinions regarding BioXCel’s stock. This week, Mizuho’s Greg Suvannavejh increased his price target for BioXCel between $18 and $24 and maintained an investment grade of buy. Goldman Sachs analyst Corinne Jenkins raised her rating on the stock from neutral to sell on December. 1. The move was likely based on the expected sales growth for the main product of the company, Igalmi (dexmedetomidine), an anti-agitation medication for bipolar or schizophrenia patients. The medication, which is administered as an under-lingual film, only launched four months ago , after its approval by Food and Drug Administration approved the drug in April. The company announced that it plans to employ an 80-person sales force this month to help promote the treatment. The first quarter after the therapy was introduced were $137,000 but the company’s management thinks there’s ample room to grow.
It is being tested in clinical trials to test its safety and efficacy in treating agitation associated with Alzheimer’s disease as well as to treat major depression. The company has a large segment of patients who could benefit from Igalmi It is estimated that there are around the 139 million instances of agitation per year throughout the U.S. that are related to mental illnesses.
What’s next?
Igalmi is BioXCel’s very first commercialized product. It is the first drug that BioXCel has marketed. biotech company suffered a loss of $41.8 million in the third quarter of 2013 and is carrying $232.3 million of cash, cash equivalents and other cash in its books. The company is likely to spend more in the coming months as it intensifies the marketing of the drug. However, investors who have a long-term view know that the reward for BioXCel (if it is approved) is likely to be a bit further in the future as it expands the approved uses for Igalmi. Due to that, there’s a lot of risk associated with this stock, but it’s not as high as it is with biotech companies in the clinical stage.
BioXcel Therapeutics Returns against. S&P
| 1 YEAR | 5 YEARS | 5 YEAR Annualized | SINCE IPO | |
|---|---|---|---|---|
| BTAI | +76.10% | +195% | ||
| S&P | -8.59% | +49.71% | +8.40% | +49% |
Assets
QuarterlyAn Annual
| Q3 2022 | YOY MODIFY | |
|---|---|---|
| Net Cash | $232.31M | -8.1% |
| Accounts Receivable | – | – |
| Inventory | 1.408 | – |
Liability
QARTERLYAnnual
| Q3 2022 | YOY Change | |
|---|---|---|
| Long Term Debt | $92.56M | +7,744.3% |
| Short Term Debt | $0.39M | +36.6% |
Ratios
QARTERLYAn Annual
| Q3 2022 | YOY Change | |
|---|---|---|
| Return On Assets | -54.2% | +32.9% |
| Return On Invested Capital | 41.4% | -77.2% |
Cash Flow
QuarterlyAn Annual
| Q3 2022 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$31.11M | +55.2% |
| Operating Free Cash Flow | -$31.11M | +55.3% |
Valuation
QuarterlyAn Annual
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY MODIFY | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 2.32 | 2.64 | 1.90 | 2.02 | -36.5% |
| Price to Sales | – | – | – | 2,417.66 | – |
| Price to Tangible Book Value | 2.32 | 2.64 | 1.90 | 2.02 | -36.5% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -13.11 | -12.39 | -5.51 | -4.92 | -78.2% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -49.9% | -58.8% | -56.6% | -73.6% | +68.5% |
| Total Debt | $1.40M | $1.33M | $62.33M | $92.96M | +6,236.4% |
